Study of INCA 0186 in Subjects With Advanced Solid Tumors

Stopped This was a strategic business decision. There were no safety concerns contributing to this decision.

Conditions

• Advanced Solid Tumors
• Squamous Cell Carcinoma of the Head and Neck (SCCHN)
• Gastrointestinal (GI) Malignancies

Interventions

• DRUG: INCA00186
• DRUG: Retifanlimab
• DRUG: INCB106385

Sponsor

Incyte Corporation